AU2015247859B2 - Dosing regimens for treating and/or preventing cerebral amyloidoses - Google Patents

Dosing regimens for treating and/or preventing cerebral amyloidoses Download PDF

Info

Publication number
AU2015247859B2
AU2015247859B2 AU2015247859A AU2015247859A AU2015247859B2 AU 2015247859 B2 AU2015247859 B2 AU 2015247859B2 AU 2015247859 A AU2015247859 A AU 2015247859A AU 2015247859 A AU2015247859 A AU 2015247859A AU 2015247859 B2 AU2015247859 B2 AU 2015247859B2
Authority
AU
Australia
Prior art keywords
addnj
period
administering
enzyme
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015247859A
Other languages
English (en)
Other versions
AU2015247859A1 (en
Inventor
Brandon Alan WUSTMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AU2015247859A1 publication Critical patent/AU2015247859A1/en
Application granted granted Critical
Publication of AU2015247859B2 publication Critical patent/AU2015247859B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015247859A 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses Ceased AU2015247859B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461979408P 2014-04-14 2014-04-14
US61/979,408 2014-04-14
US14/684,967 US9675627B2 (en) 2014-04-14 2015-04-13 Dosing regimens for treating and/or preventing cerebral amyloidoses
US14/684,967 2015-04-13
PCT/US2015/025733 WO2015160796A1 (en) 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses

Publications (2)

Publication Number Publication Date
AU2015247859A1 AU2015247859A1 (en) 2016-12-01
AU2015247859B2 true AU2015247859B2 (en) 2020-03-26

Family

ID=53015935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015247859A Ceased AU2015247859B2 (en) 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses

Country Status (10)

Country Link
US (2) US9675627B2 (enExample)
EP (1) EP3131547A1 (enExample)
JP (1) JP6662789B2 (enExample)
KR (1) KR20170003576A (enExample)
CN (1) CN107148270A (enExample)
AU (1) AU2015247859B2 (enExample)
CA (1) CA2945707A1 (enExample)
HK (1) HK1243643A1 (enExample)
SG (1) SG11201610349SA (enExample)
WO (1) WO2015160796A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2490712T3 (pl) * 2009-10-19 2015-12-31 Amicus Therapeutics Inc Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz
US9994589B2 (en) 2015-12-14 2018-06-12 Amicus Therapeutics, Inc. Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049787A1 (en) * 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
CA2526173A1 (en) 2003-05-22 2004-12-02 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
CN104771402A (zh) 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
WO2007137072A2 (en) * 2006-05-16 2007-11-29 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
EP2040548B1 (en) 2006-06-23 2012-05-02 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of beta -glucocerebrosidase
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2011011181A1 (en) 2009-07-01 2011-01-27 Amicus Therapeutics, Inc. Pharmacological chaperones for the treatment of alzheimer's disease
CN107088225A (zh) * 2011-03-11 2017-08-25 阿米库斯治疗学公司 治疗法布里病的给药方案
EP2793872B1 (en) * 2011-12-22 2021-03-10 Centogene IP GmbH Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
ES2859761T3 (es) * 2012-05-03 2021-10-04 Amicus Therapeutics Inc Pautas posológicas para el tratamiento de enfermedad de Pompe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049787A1 (en) * 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases

Also Published As

Publication number Publication date
SG11201610349SA (en) 2017-01-27
CN107148270A (zh) 2017-09-08
US20170273996A1 (en) 2017-09-28
KR20170003576A (ko) 2017-01-09
US9675627B2 (en) 2017-06-13
JP6662789B2 (ja) 2020-03-11
AU2015247859A1 (en) 2016-12-01
WO2015160796A1 (en) 2015-10-22
HK1243643A1 (zh) 2018-07-20
JP2017511372A (ja) 2017-04-20
CA2945707A1 (en) 2015-10-22
EP3131547A1 (en) 2017-02-22
US20160008383A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
EP2490712B1 (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
Bellettato et al. Pathophysiology of neuropathic lysosomal storage disorders
CN104383556B (zh) 突触核蛋白病的治疗
JP5303458B2 (ja) β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
ES2705027T3 (es) Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
US20170304266A1 (en) (3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
RS66094B1 (sr) Migalastat za primenu u metodama lečenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu
AU2015247859B2 (en) Dosing regimens for treating and/or preventing cerebral amyloidoses
Shi et al. PGRN as an emerging regulator of lipid metabolism in neurodegenerative diseases
US10179128B2 (en) Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
US20130102538A1 (en) Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
TW201620517A (zh) 用於治療及／或預防腦澱粉樣變性（Ｃｅｒｅｂｒａｌ Ａｍｙｌｏｉｄｏｓｅｓ）之給藥方案
HK1175400B (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
JP2024084670A (ja) ミガラスタットの薬物動態を改善する方法
HK1215534B (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired